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Abstract
Hematopoietic stem cell transplantation (HSCT) is currently the only established cure
for sickle cell disease (SCD). Replacement of the stem cell that has the defective beta
globin allele with the normal gene decreases hemoglobin S and the risk of complications
of SCD. The first case reported was a girl with acute myeloid leukemia and SCD who
received HSCT and achieved long-term SCD and leukemia-free survival. Given the
favorable outcomes of HSCT with thalassemia major using myeloablative preparative
regimens, this approach became widely used in the initial studies of HSCT in SCD. The
current standard of care is to use a myeloablative stem cell transplantation in patients
with  severe  disease  who  have  human  leukocyte  antigen–identical  sibling.  HSCT
improves organ function, quality of life, and overall and disease-free survival. However,
this is associated with high risk of gonadal dysfunction and graft versus host disease in
addition to the mortality associated with the myeloablative HSCT. Reduced-intensity
HSCT has also been reported with high rates of engraftment and favorable outcomes.
This has been introduced to lower the gonadal dysfunction, mortality, and graft versus
host  disease  associated  with  myeloablative  approaches.  Other  approaches  include
HSCT using matched unrelated donors, cord blood units, and human leukocyte antigen
haploidentical donors. Unfortunately, graft rejection is a common complication with
these approaches. In this chapter, we review the indications of HSCT for SCD and
outcomes of different transplant strategies including alternative donor transplant, graft
rejection, and infertility after transplantation.
Keywords: sickle cell disease, hemoglobinopathy, stem cell transplantation, myeloa-
blative, reduced intensity, graft rejection
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1. Introduction
Replacement of the stem cell that has the defective beta globin allele with the normal gene
decreases Hemoglobin S and the risk of complications of sickle cell disease (SCD). This could
be achieved through gene therapy or allogeneic  Hematopoietic  stem cell  transplantation
(HSCT). The proof of principle case was an 8-year-old girl with acute myeloid leukemia (AML)
and SCD who received HSCT for AML. Her AML was in remission 22 months posttransplan-
tation and she was free of SCD.
The utility of HSCT in patients with SCD was shown in multiple studies since over 20 years
with disease-free survival (DFS) of 90% [1, 2]. The improved organ function and decreased risk
of SCD-related complications are attractive goals of therapy in these patients [3, 4]. Further-
more, SCD cure by HSCT is associated with improved quality of life scores in the physical,
social, and emotional domains [5, 6].
Despite the promising results of HSCT in SCD, there are a number of unresolved issues limiting
its’ widespread application. The number of HSCT for SCD remains less than expected and cost
is one of the major factors behind this knowing that the disease is much more prevalent in
countries with low income [7, 8]. The course and severity of the disease cannot be accurately
predicted with the currently available tools making it difficult to recommend HSCT early
before end organ damage [9, 10]. This is especially important in children without end organ
damage where one can debate the utility of HSCT for mild disease before damage occurs. In
addition, most of the preparative regimens used are myeloablative [11] and these have led to
high rates of gonadal dysfunction in patients who have not yet completed their family. This is
even more of an issue in cultures where SCD is prevalent. Another issue is the limited number
of siblings in families with SCD potentially giving rise to two problems, the low probability of
finding a matched sibling donor (MSD) and the risk of mobilization of siblings with sickle cell
trait. Unfortunately, for patients with no MSD, the probability of finding a matched unrelated
donor (MUD) is low [12]. The theoretical risk of mobilizing donors with sickle cell trait is
probably not real and the safety has been shown in multiple small studies [13].
2. Indications of HSCT in SCD
HSCT is the only curative treatment option for patients with SCD. However, it can be associated
with significant toxicities making it a good treatment option for patients with severe disease
who have a human leukocyte antigen (HLA) MSD [11]. Therefore, its initial use was limited
to severe SCD, which is defined by the presence of one or more of SCD complications that
include stroke or central nervous system event lasting longer than 24 hours, acute chest
syndrome with recurrent hospitalizations or previous exchange transfusions, recurrent
vasoocclusive pain (≥2 episodes per year for several years, recurrent priapism), impaired
neuropsychological function and abnormal cerebral MRI scan, stage I or II sickle lung disease,
sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30–50% of
the predicted normal value), bilateral proliferative retinopathy and major visual impairment
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in at least in one eye, osteonecrosis of multiple joints, and/or red cell alloimmunization (≥2
antibodies) during long-term transfusion therapy [14]. Unfortunately, besides fetal hemoglo-
bin there are no well-established prognostic markers that can indicate which patients are most
likely to develop severe disease making it difficult to determine risk benefit ratio of HSCT for
patients with less severe disease.
The indications above were adopted from the inclusion criteria of the first major trial of HSCT
in patients with SCD involving 22 children [14]. There is no evidence-based medicine guideline
to inform practice and all available guidelines are expert and consensus recommendations. A
recent evidence-based focused review [15] divided the indications according to the donor
source; however, the quality of evidence is not superior to expert and consensus recommen-
dations. The review suggests that as the severity of SCD worsens, more experimental ap-
proaches could be utilized. Below, we list the indications of HSCT according to the donor
source as recommended in the review [15].
When MSD is available:
• Stroke or high risk of stroke (elevated transcranial Doppler velocity).
• Recurrent acute chest syndrome.
• Recurrent severe acute painful crises.




• Bone and joint involvement.
• Sickle retinopathy.
When MUD is available:
• Stroke or high risk of stroke (elevated transcranial Doppler velocity).
• Recurrent acute chest syndrome.
• Recurrent severe acute painful crises.




• Bone and joint involvement.
When neither MSD nor MUD is available, mismatched marrow, haploidentical, or unrelated
cord blood donor transplantation could be considered when:
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• Recurrent stroke in patients on chronic transfusion therapy.
• Failure to tolerate the supportive care (e.g., chronic transfusion) in severe SCD.
HSCT for SCD offers a cure, but with variable morbidity especially graft versus host disease
(GvHD) and treatment-related mortality. The risk benefit ratio should be considered when
offering HSCT for patients and their families. The risks of complications and options should
be discussed with the patients and their families for shared decision making. Outcomes and
the nature of evidence for the available transplant donor should be balanced with the severity
of SCD and the two should be presented to the patients and their families before a decision to
undergo the procedure is made. Finally, the new and experimental approaches should only be
performed in experienced transplant centers. Comparison of different transplant outcomes
between the different transplant strategies is summarized in Figure 1.
Figure 1. Comparison of transplant outcomes between different transplant strategies. Abbreviations: MSD-MA, match-
ed sibling donor-myeloablative; MSD-RIC, matched sibling donor-reduced intensity conditioning; RCBT, related cord
blood transplantation; UCBT, unrelated cord blood transplantation; OS, overall survival; DFS, disease free survival;
aGvHD, acute graft versus host disease; cGvHD, chronic graft versus host disease. Note: The numbers in the figure are
summarized for representative study of each transplant strategy. In MSD-MA study, the aGvHD rate only represents
the high grade.
3. HSCT from MSD using a myeloablative preparative regimen
Preparative regimens and outcomes of HSCT in thalassemia major have influenced the
strategies used in HSCT in patients with SCD. Myeloablative, nonradiation-based regimens
were commonly used with high rates of engraftment and DFS [11]. The most commonly used
was busulfan with cyclophosphamide at myeloablative doses and this became the preferred
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regimen in many of the future SCD transplant studies [11]. One of the earliest prospective
studies was reported by Walters et al. [14]. In this study, a myeloablative regimen using
busulfan and cyclophosphamide with antithymocyte globulin (ATG) was used in 22 patients
with severe SCD. With a median follow-up of 2 years, overall survival (OS), and DFS were 91
and 73%, respectively. The high grade acute graft versus host disease (aGvHD) and chronic
graft versus host disease (cGvHD) rates were 15 and 12%, respectively.
Another study reported by Bernaudin et al. [3] included 87 children with SCD, most of which
had cerebrovascular event as the indication of the HSCT. The preparative regimen used was
busulfan with cyclophosphamide at myeloablative doses. The ATG was later added to the
regimen. The DFS was 91% with OS of 96%. The rates of high grade aGVHD and cGvHD were
20 and 13%, respectively. Two other studies using a similar preparative regimen reported OS
of 85–96% [16, 17]. Given the high rates of DFS and OS, myeloablative preparative regimen
using MSD is considered the standard of care for patients with SCD undergoing HSCT.
4. HSCT from MSD using reduced intensity preparative regimen
After the encouraging results of myeloablative preparative regimens in children, attempts to
include adults using reduced intensity regimens were tried. The rationale was based on the
assumption that mixed chimerism may be enough to ameliorate the complications of SCD and
unlike in malignant conditions, myeloablation is not needed [18]. The use of reduced intensity
regimens has expectedly resulted in less transplant-related organ dysfunction and may have
preserved fertility, which is an important limitation of myeloablative transplantation.
Hsieh et al. [19, 20] investigated this approach in 30 adult patients using peripheral stem cell
transplants. The preparative regimen constituted of 300 cGy of total body irradiation (TBI)
with alemtuzumab and using sirolimus for GvHD prophylaxis. Most patients (26 out of 30)
had a successful engraftment and no treatment related mortality, or GvHD was reported. This
was attributed to the intensive GvHD prophylaxis using alemtuzumab and sirolimus. The DFS
of 90% and OS of 100% were very encouraging. No data are yet available on the gonadal
dysfunction of this approach.
Another study by Bhatia et al. [21] using a reduced toxicity, albeit myeloablative, preparative
regimen with busulfan, fludarabine, and alemtuzumab in 18 patients with a median age of 8.9
years reported 17% of high grade aGvHD and 11% cGvHD. There was no graft rejection and
all patients were alive at the time of the study report.
5. HLA matched unrelated donor transplantation
The probability of finding an HLA MUD is lower than desired in patients with SCD. In a report
from the National Marrow Donor Program, the probability of finding a 6/6 MUD for patients
with SCD was 60% [12]. The probability is much lower, 20%, when a more strict criteria using
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8/8 matching at the allelic level is used [22]. This is likely due to the underrepresentation of the
haplotypes of this genetic group in the international stem cell donor registries. Overall, the
studies of MUD transplantations in SCD are scarce and include very small number of patients.
There is a high risk of graft failure and other transplant-related complications with the MUD
approach [23]. A number of prospective studies are currently running and results should be
available in the near future. At this time, transplantation for patients with SCD from a MUD
donor should only be done in a clinical trial setting.
6. Related cord blood transplantation (RCBT)
Related cord blood transplantation (RCBT) achieves OS and DFS rates similar to that of MSD
transplantation, except for a significantly longer engraftment time for neutrophils and
platelets. In a comparative study [24] of bone marrow HSCT versus RCBT in patients with
hemoglobinopathies, 30 patients received RCBT for SCD. Patients in the RCBT group were
mostly children and received a myeloablative preparative regimen. Serotherapy was given in
more than half of the patients. The median total nucleated count (TNC) was 3.9 × 107/kg. With
a median follow-up of 70 months, the DFS at 6 years for this group was 90% and no patient
developed grade IV aGvHD or extensive cGvHD. The cumulative incidence of primary graft
failure in the entire RCBT group was 9%. For those who engrafted, the cumulative incidence
of day 60 neutrophil and day 180 platelet recovery was 90% (median 23 days) and 83% (median
38 days), respectively. Although the results of RCBT are not markedly different than that of
MSD, the delayed recovery of neutrophils and platelets increases the risk of infection and
bleeding complications, particularly, the central nervous system. In addition, the probability
of finding RCBT unit is limited given the limited number of siblings in families with SCD.
Finally, the availability of the RCBT is limited in areas where it is mostly needed, such as Africa.
7. Unrelated cord blood transplantation (UCBT)
The outcomes of unrelated cord blood transplantation (UCBT) are inferior to that of RCBT for
patients with SCD. Two of the largest series are the Eurocord study [25] and the SCURT trial
[26]. In the Eurocord study [25], 16 patients were transplanted with a mixture of myeloablative
(10 received busulfan with cyclophosphamide or fludarabine) and reduced intensity prepa-
rative regimens (6 received fludarabine with busulfan, melphalan, or cyclophosphamide).
Most patients received serotherapy with either ATG or alemtuzumab. All units were at least
4/6 HLA matched with a median TNC of 6 and 4.9 × 107/kg at the time of collection and infusion,
respectively. The engraftment was only 60% with a 2-year OS and DFS of 94 and 53%. The rates
of acute and chronic GvHD were 23 and 16%, respectively. In the SCURT trial [26], only eight
patients were studied and all received similar nonmyeloablative preparative regimen using
melphalan, fludarabine with alemtuzumab. All patients received at least 5/6 HLA matched
units with a median TNC of 6.4 × 107/kg. Only three patients engrafted and one died of
extensive cGvHD. In a similar small study [27] of eight patients (only five evaluable) using
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busulfan, fludarabine, and alemtuzumab, only 63 and 50% engrafted neutrophils and platelet,
respectively. Twenty-five percent of patients had high grade aGvHD. The overall event-free
survival and OS at 2 years were 50 and 63%, respectively.
Given the high rates of graft rejection and the delayed immune reconstitution that is associated
with UCBT, this modality should only be used in a study. Possible ways to improve this
modality are using higher intensity preparative regimens, using higher TNC, and lower
mismatches. Double cord blood or cord blood supplemented with bone marrow are two
promising options especially with children.
8. Haploidentical stem cell transplantation
HLA haploidentical HSCT is a promising alternative for patients with SCD with no available
MSD. Nevertheless, it is characterized by high rate of graft failure. In a prospective study of
17 patients with SCD [28], 14 patients received a haploidentical transplantation. The prepara-
tive regimen was similar to the most widely used T cell-replete haploidentical HSCT with
cyclophosphamide, fludarabine, and TBI using bone marrow as the stem cell source. The
mycophenolate and the calcineurin inhibitor were used in addition to the posttransplant
cyclophosphamide as aGvHD prophylaxis. In this study, ATG was added for 3 days starting
Day -9. With a median follow-up 711 days, 10 patients were asymptomatic from SCD and 6
stopped immunosuppression. No deaths were reported and only one patient had GvHD of
the skin. Unfortunately, the probability of graft failure was high at 43%. The use of haploi-
dentical transplantation in SCD should be only used in a study setting.
9. Graft rejection
HSCT using myeloablative preparative regimen and HLA MSD has relatively low risk of graft
rejection [11]. Bernaudin et al. reported an overall cumulative incidence of rejection of 7.0% at
5 years [3]. The addition of ATG to the preparative regimen resulted in a significant decrease
in the 5-year cumulative incidence of rejection from 22.6 to 2.9% in patients who received ATG.
A number of other studies using similar myeloablative regimens reported rejection rates of up
to 10% [14, 17].
The rejection rate is different outside myeloablative transplantation; graft loss may not be
uncommon complication of transplant using nonmyeloablative preparative regimens [11].
Attempts to improve this with higher intensity of nonmyeloablative regimens improved the
rejection rate but with high proportion of mixed chimerism [20, 29, 30]. The mixed chimerism,
if stable, may be enough to ameliorate the complications SCD [18]. Locatelli et al. reported
rejection rate of 9% with RCBT which is similar to the MSD transplantation using myeloablative
protocol. The URCB and the HLA haploidentical transplantation are associated with high risk
of graft rejection of over 40% [25, 28, 31].




The risk and fear of infertility is a major limiting factor on the widespread use of HSCT in
patients with SCD. This high risk of infertility from HSCT in a benign condition limits the
referral of patients. In addition, it also adds to the worries and deferral factors for patients to
undergo the procedure.
The assessment of infertility post HSCT in children and young adults is difficult and only
surrogate endpoints like gonadal dysfunction are used which limits the interpretation of
studies of fertility post HSCT. The use of a standard approach of HSCT in SCD is associated
with high risk of gonadal dysfunction. In the prospectively U.S. study [4], the use of a mye-
loablative preparative regimen lead to hypogonadotropic hypogonadism in most of the
pubertal males and primary ovarian failure in the majority of postpubertal females. In another
study using a similar preparative myeloablative regimen with ATG or radiation [17], all
patients who were transplanted after puberty had gonadal dysfunction. The use of reduced
intensity preparative regimens may lower the risk of gonadal dysfunction; however, it is yet
to be shown prospectively.
11. Quality of life and long-term complications
Sickle cell disease impacts health related quality of life (HRQL) in children and adults [32–35].
The impact is worse in females and older children [34]. In adults, HRQL scores may be similar
to patients receiving hemodialysis [36]. Unfortunately, it is not yet known with confidence that
HSCT improves HRQL in patients with SCD. Studies addressing this question are small in
number and sample size and predominantly examined reduced intensity HSCT [5, 6, 37].
HRQL scores improved in patients who received reduced intensity chemotherapy-based
HSCT. The improvement was more marked with longer follow-up after transplant [5]. The
improvement was noticed across all domains of and in parent-reported HRQL. Similar results
were observed in patients who received chemotherapy-free (TBI-/alemtuzumab-based)
HSCT [37]. The improvement in scores included the bodily pain, general health and vitality.
Long-term complications and reintegration have not been well addressed in literature despite
a relatively long history of HSCT in SCD. In a study with a median follow-up of 9 years of 22
children with SCD who received HSCT from MSD [38], the overall survival was 93% and there
was no recurrence of graft failure. This study was able to demonstrate that even with long-
term follow-up; the engraftment and protection against SCD-related complications were
sustained.
12. Conclusions
HSCT for severe SCD offers cure and a chance of amelioration of SCD-related complications.
Myeloablative HSCT using HLA MSD remains the standard of care. RCBT offers similar results
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but longer time to count recovery. Transplantation from MUD, UCBT, or HLA haploidentical
donors should only be practiced in a study setting in experienced transplant centers. Reduced
intensity transplantations from MSD offer stable mixed chimerism and may decrease the risk
of gonadal dysfunction in these young patients. Attempts to expand the pool of donors should
continue.
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